TGA guidance for SaMD Regulatory “Carve Out”

19 November 2020 |

Electronic Medical Record

Following a public consultation on the Regulation of software, including Software as a Medical Device (SaMD) in early 2019, the TGA introduced several regulatory changes, including:

  • new classification rules for medical device software-based products (except IVD medical device software); and
  • changes to the Essential Principles for safety and performance of software-based medical devices, to improve the clarity of requirements.

Consequent to these changes, the new regulatory framework considers the risk of patient harm where incorrect information is the source of harm. Majority of the new requirements were meant to come into effect from 25 August 2020 with a four-year transition period. However, in consideration of the COVID-19 pandemic, the Australian Government delayed the commencement of a number of medical device reforms. The Australian Medical Device Regulations have now been amended to delay implementation of the following reforms:

  • 25 February 2021 for medical device software, personalised medical devices (including 3D printed devices) and systems or procedure packs; and
  • 25 November 2021 for reclassification of certain devices.

It is important to note that the delay to the commencement of the reforms does not change the end of the transition period, which remains as at 31 October 2024.

In March 2020, the TGA undertook another public consultation seeking feedback on a proposal to “carve out” from Therapeutic Goods Regulation some low-risk software medical devices, or devices that were subject to other oversight arrangements, such as NPAAC and/or NATA accreditation. Based on an analysis of the feedback received, in August 2020 the TGA published proposed categories of software for Exemption or Exclusion from the regulations.

The TGA is currently in the process of finalising draft instruments to Exempt certain software based on conditional criteria for Clinical Decision Support Systems, and Exclude the following groups of software:

  1. Consumer health products – prevention, management and follow up devices that do not provide specific treatment or treatment suggestions;
  2. Enabling technology – for telehealth, remote diagnosis, healthcare or dispensing;
  3. Digitisation – of paper-based or other published clinical rules or data including simple dose calculators and Electronic Patient Records;
  4. Analytics – population-based analytics that do not drive outcomes for individuals, including data analytics; and
  5. Laboratory Information Management Systems – including pathology and radiology use cases and software to automate workflows, integrate instruments, manage orders and samples and associated information (given these systems are already subject to oversight through other mechanisms).

To assist sponsors meet their obligations prior to the amended regulations affecting medical device software from 25 February 2021, the TGA is developing a package of guidance materials and fact sheets, including flowcharts and examples, to be published on their website by the year-end 2020.

We offer deep support for navigating international regulatory processes.  Whether it’s a TGA application, a strategy for MDR transition, a US presubmission or 510(k) filing, or specific help with regulatory documents (e.g. Clinical Evaluation Reports), or an update of your quality system to gain MDSAP. We understand you need a commercial approach which delivers viable options. Reach out today and start a conversation. Contact us to discuss your needs and how we can help. You can drop us an email [email protected] or call 1 888-271-5063 (US toll free) ♦ +61 2 9906 2984 (Sydney)

Disclaimer
The views and options expressed in this article are those of the author/s and do not necessarily reflect the views of Brandwood CKC Pty Ltd ACN 128 762 505.

The information presented in this article is of a general nature only and does not consider the particular circumstances of your business. Prior results and case studies do not guarantee a similar outcome in future. You should not rely on this information, and you should seek specific advice for your particular business needs.

Where indicated, certain content has been sourced from third parties; we have not independently verified it. Neither Brandwood CKC nor the author makes any warranty as to the accuracy, completeness or reliability of this article, nor do those parties accept any liability or responsibility arising in any way from omissions or errors contained in the content.

Search

Recent Posts

Categories

Categories

Archives

Archives

Archives